LB751 COVID-19 complications in patients with Hidradenitis Suppurativa: A multicenter study

Raiker, R.; Pakhchanian, H.; Phan, K.

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disorder that causes abscesses in intertriginous areas and is also associated with numerous other conditions. There is limited literature on the outcomes of COVID patients with HS so the goal was to investigate the impact of AD on COVID outcomes. A retrospective cohort study was done using TriNetX, a federated real time database of 63 million records. COVID patient cohorts were identified by validated ICD-10 and serology codes per CDC guidelines from 1/20/2020 to 2/23/2021. A 1:1 matched propensity score analysis was conducted, adjusting for comorbidities and demographics, to calculate adjusted Risk Ratios (aRR) with 95% CI. 30-day COVID complications were examined with severe COVID being defined as a composite of mortality and ventilation. Subgroup analyses were also performed for HS patients on systemic antibiotics. In a matched sample of 2004 patients in each cohort, there was no statistically significant difference between HS-COVID patients and non-HS COVID patients in hospitalization (0.93[0.8-1.1]), acute respiratory distress syndrome (1.31 [0.8-2.2]), mechanical ventilation (1.06 [0.7-1.6]), mortality (1.00 [0.6-1.8]), and severe COVID (1.07 [0.8-1.5]) but there was a difference in sepsis (1.37 [1.0-1.9]). Subgroup analysis revealed that HS-COVID patients with a one-year history of systemic antibiotic use were at a higher risk for hospitalization (1.27 [1.01-1.6]) compared to HS-COVID patients without one-year history of systemic antibiotics wheras all other outcomes assessed had no differences. HS-COVID patients are not at higher risk for more severe COVID outcomes compared to COVID patients without HS. However, HS patients with a history of systemic antibiotics are at a higher risk for hospitalization compared to HS patients without a history of systemic antibiotics. Further studies are warranted to visit the longer-term impacts of COVID on HS patients.